PT  - JOURNAL ARTICLE
AU  - M. J. Piccart
AU  - K. Bertelsen
AU  - G. Stuart
AU  - J. Cassidy
AU  - C. Mangioni
AU  - E. Simonsen
AU  - K. James
AU  - S. Kaye
AU  - I. Vergote
AU  - R. Blom
AU  - R. Grimshaw
AU  - R. Atkinson
AU  - K. Swenerton
AU  - C. Trope
AU  - M. Nardi
AU  - J. Kaern
AU  - S. Tumolo
AU  - P. Timmers
AU  - J.-A. Roy
AU  - F. Lhoas
AU  - B. Lidvall
AU  - M. Bacon
AU  - A. Birt
AU  - J. Andersen
AU  - B. Zee
AU  - J. Paul
AU  - S. Pecorelli
AU  - B. Baron
AU  - W. Mcguire
TI  - Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer
AID  - 10.1136/ijgc-00009577-200311001-00003
DP  - 2003 Oct 01
TA  - International Journal of Gynecologic Cancer
PG  - 144--148
VI  - 13
IP  - Suppl 2
4099  - http://ijgc.bmj.com/content/13/Suppl_2/144.short
4100  - http://ijgc.bmj.com/content/13/Suppl_2/144.full
SO  - Int J Gynecol Cancer2003 Oct 01; 13
AB  - Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European–Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin–paclitaxel regimen over cisplatin–cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.